Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asston PharmaceuticalsBOM:544445 -0.59%19 EBITDA Margin % is 51.51% as of Mar. 2026, which is 136% above its 10-year median of 21.79. GuruFocus rates BOM:544445 with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, Asston Pharmaceuticals ranks better than 72.74% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Asston Pharmaceuticals EBITDA Margin % Related Terms
Asston Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Asston Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Asston Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asston Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Asston Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Asston Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asston Pharmaceuticals (BOM:544445) has a EBITDA Margin % of 51.51% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Asston Pharmaceuticals and its competitors. This is 136% above median its historical median of 21.79. Over the past decade, Asston Pharmaceuticals' EBITDA Margin % has ranged from 6.17 to 32.51. According to the industry distribution chart, Asston Pharmaceuticals ranks #262 out of 961 companies in the Drug Manufacturers industry, placing it in the top 27.3%.
Is Asston Pharmaceuticals' EBITDA Margin % too high?
Asston Pharmaceuticals' current EBITDA Margin % of 51.51% is 136% above median its 10-year median of 21.79. Over the past 10 years, this metric has ranged from a low of 6.17 to a high of 32.51. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Asston Pharmaceuticals' value of 51.51% is 314.1% above this industry median. Based on the distribution chart, Asston Pharmaceuticals ranks #262 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Asston Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Asston Pharmaceuticals' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Asston Pharmaceuticals ranks #262 out of 961 companies for EBITDA Margin %. This puts Asston Pharmaceuticals in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Asston Pharmaceuticals' value of 51.51% is 314.1% above this benchmark. Historically, Asston Pharmaceuticals' own EBITDA Margin % has ranged from 6.17 to 32.51 over the past decade. While the company's 10-year median is 21.79 vs. the industry median of 12.44, Asston Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asston Pharmaceuticals's current EBITDA Margin % of 51.51% is 314.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Asston Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asston Pharmaceuticals's current EBITDA Margin % is 51.51%, which is 136% above median its own 10-year median of 21.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asston Pharmaceuticals stock overvalued right now?
Asston Pharmaceuticals (BOM:544445) has a current EBITDA Margin % of 51.51%. The current EBITDA Margin % is 51.51%, which is 136% above median its 10-year median of 21.79 and 314.1% above the Drug Manufacturers industry median of 12.44. Asston Pharmaceuticals' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Asston Pharmaceuticals (BOM:544445), the current EBITDA Margin % is 51.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asston Pharmaceuticals Ltd manufactures and exports pharmaceutical and nutraceutical products. The company produces a wide range of healthcare items including tablets, capsules, syrups, sachets, ointments, creams, gels, and lotions. It serves markets in West and South Africa, with expansions planned into Asian countries. Asston conducts business through export sales, contract manufacturing and loan license arrangements via merchant exporters, and domestic sales within India. Revenue is generated through the sale of branded and generic pharmaceutical formulations along with nutraceutical products. The business operations are broadly categorized into: Domestic Formulations, Export Formulations, APIs and Intermediates, and Research and Development.
19GF Score
Get the complete analysis for BOM:544445
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544445 has been successfully added to your 
